Palvella Therapeutics (PVLA) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Schrodinger (SDGR) over the past year, gaining 75.5% versus a gain of 27.4%. Over five years, SDGR leads with a -52.3% price change compared with -63.6% for PVLA. Schrodinger is the larger company by market cap ($1.97 billion vs $1.89 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | SDGR |
|---|---|---|
| Share price | $131.34 | $26.39 |
| Market cap | $1.89B | $1.97B |
| 1-day change | +0.57% | -3.30% |
| YTD return | +25.48% | +47.60% |
| 1-year return | +75.47% | +27.36% |
| 5-year return | -63.60% | -52.33% |
| EPS (TTM) | $-4.85 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $161.38 | $33.78 |
| 52-week low | $65.93 | $10.95 |
| Distance from 52-week high | -18.61% | -21.88% |
| Analyst consensus | none | none |
| Avg. price target upside | +75.52% | -18.79% |
| Average volume | 211.36K | 1.74M |
| Shares outstanding | 14.41M | 65.64M |
| Employees | 29 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed SDGR by 48.1 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
PVLA vs SDGR FAQ
Which is bigger, Palvella Therapeutics or Schrodinger?
Schrodinger (SDGR) is larger, with a market capitalization of $1.97B compared with $1.89B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, PVLA or SDGR?
PVLA returned +75.47% over the past 12 months, compared with +27.36% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.